BREAKING NEWS: FDA Approves Darolutamide for Metastatic Hormone-Sensitive Prostate Cancer (read more here).
Go here to learn more or to get a mailed copy.
Home » Bio
Application of Nanotechnology to Novel Models of..
University of North Carolina
Identification of molecular drivers of prostate cancer..
Dr. Efsathiou earned both MD and PhD..
Eleni Efstathiou, MD, PhD:
The University of Texas MD Anderson Cancer Center – Houston, TX
Molecular imaging of prostate cancer to determine..
Michael Evans, PhD:
University of California, San Francisco
Charles Sawyers, MD and Jason Lewis, PhD
Exploiting the genetics of advanced prostate cancer for tumor detection and therapy with transferrin-based radionuclides
Jason A. Efstathiou, MD, DPhil:
Massachusetts General Hospital
Matthew R. Smith, MD, PhD
Predictors of Response and Failure to Radiotherapy for Prostate Cancer in a Randomized Trial
View All Board Members here.
ChairmanEderer Investment Company
PresidentEvans & Co., LLC
Managing PartnerFlintridge Capital Investments, LLC
Professor Rosalind Eeles is searching for genetic..
Institute for Cancer Research